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Summary. Background: Currently, there is no approved reversal agent for direct activated factor Xa (FXa) inhibitors; however, several agents are under investigation, including prothrombin complex concentrates (PCCs).
Objective: This open-label, randomized, placebo-controlled, three-period crossover study assessed the effect of two four-factor PCCs on apixaban pharmacodynamics and pharmacokinetics in 15 healthy subjects. Methods: Subjects received apixaban 10 mg twice daily for 3 days. On day 4, 3 h after apixaban, subjects received a 30-min infusion of 50 IU kg À1 Cofact, Beriplex P/N (Beriplex), or saline. Change in endogenous thrombin potential (ETP), measured with a thrombin generation assay (TGA), was the primary endpoint. Secondary endpoints included changes in other TGA parameters, prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time, anti-FXa activity, apixaban pharmacokinetics, and safety. Results: Apixaban-related changes in ETP and several other pharmacodynamic measures occurred following apixaban administration. Both PCCs reversed apixaban's effect on ETP; the differences in adjusted mean change from pre-PCC baseline to end of infusion were 425 nM min (95% confidence interval [CI] 219.8-630.7 nM min; P < 0.001) for Cofact, and 91 nM min (95% CI À 31.3 to 212.4 nM min; P > 0.05) for Beriplex. Both PCCs returned ETP to pre-apixaban baseline levels 4 h after PCC infusion, versus 45 h for placebo. For both PCCs, mean ETP peaked 21 h after PCC initiation, and then slowly decreased over the following 48 h. Both PCCs reversed apixaban's effect on TGA peak height, PT, and INR.
Introduction
Direct oral anticoagulants (DOACs), including direct thrombin inhibitors such as dabigatran and direct activated factor Xa (FXa) inhibitors such as apixaban, rivaroxaban, and edoxaban, are alternatives to vitamin K antagonists (VKAs) such as warfarin. In cases of VKArelated bleeding, the anticoagulant effect of VKAs can be mitigated by vitamin K, with or without four-factor prothrombin complex concentrates (PCCs) [1, 2] , and idarucizumab was recently approved for reversal of dabigatran's anticoagulant effects [3, 4] . However, there are no approved reversal agents for direct FXa inhibitors; thus, there are concerns regarding managing bleeding with their use [5] . Several approaches to mitigating the anticoagulant effects of direct FXa inhibitors are being evaluated, including specific reversal agents such as andexanet alfa [6, 7] and ciraparantag (aripazine, PER977) [8] , procoagulant agents such as recombinant activated FVII (FVIIa) and PCCs, and plasma exchange [9, 10] .
PCCs are concentrated, human hemostatic blood products containing vitamin K-dependent clotting factors (three-factor PCCs -FII, FIX, and FX; four-factor PCCs -FII, FVII, FIX, and FX). PCCs may also contain coagulation inhibitors such as heparin, antithrombin, protein C, protein S, and protein Z, which stabilize the formulation and/or mitigate thrombotic risk [11] . Clotting factors provided by PCC products are generally not in an activated form, and require activation via the coagulation cascade, with the exception of FEIBA, which contains FVIIa and inactivated forms of FII, FIX, and FX [11] . Regardless of preparation, PCCs have been used to reverse VKA-related bleeding; however, only Kcentra, a four-factor PCC, has been approved in the USA for the urgent reversal of VKAs in adult patients with acute major bleeding or a need for urgent surgery or invasive procedures [12] .
Reversal of the pharmacodynamic (PD) effects of apixaban by PCCs has been demonstrated in multiple preclinical (animal and in vitro bleeding models) and clinical (phase 1, healthy volunteer) studies [13] [14] [15] [16] [17] . The primary objective of this study was to evaluate the effects of two four-factor PCCs (Table 1) , i.e. Cofact (a heparin-free formulation; Sanquin, Amsterdam, the Netherlands) and Beriplex P/N (Beriplex; a formulation containing heparin; marketed in the USA as Kcentra; CSL Behring, Marburg, Germany), on apixaban-mediated changes in endogenous thrombin potential (ETP) in healthy subjects [18, 19] . Secondary objectives included assessment of the effects of Cofact and Beriplex on apixaban-mediated changes in other thrombin generation assay (TGA) parameters (lag time, peak, time to peak, and velocity index), prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (APTT), and antiFXa activity (AXA), and assessment of apixaban pharmacokinetics, safety, and tolerability, with and without four-factor PCC administration.
Materials and methods

Study design
This was an open-label, randomized, placebo-controlled, three-period crossover study (EUDRACT No. 2013-000646-18) assessing the effects of Cofact and Beriplex on apixaban pharmacodynamics in healthy subjects (Fig. 1 ). Subjects were randomized on day 1 period 1 to one of six possible treatment sequences, according to a computergenerated randomization scheme. On days 1-3 of each period, subjects received 10 mg of oral apixaban twice daily. On the morning of day 4, subjects received a single dose of 10 mg of apixaban, followed 3 h later by a 30-min intravenous infusion of either 50 IU kg À1 Cofact, 50 IU kg
À1
Beriplex, or placebo saline solution. There was an 11-day washout between periods. All subjects remained in the clinic for at least 72 h after the start of infusion. Bristol-Myers Squibb (Princeton, NJ, USA) supplied apixaban 5-mg tablets. Commercial Cofact, Beriplex, sterile water for injection and normal saline solution were purchased by the investigator.
The study was conducted at a single center, Parexcel International GmbH, Berline, Germany, in accordance with Good Clinical Practice and the Declaration of Helsinki, and was approved by the independent ethics committee of the state of Berlin, Germany (EthikKommission des Landes Berlin, Landesamt F€ ur Gesundheit Und Soziales [Gesch€ aftsstelle]).
Study population
Healthy men and women aged 18-45 years with a body mass index of 18-30 kg/m 2 who provided written informed consent were eligible for the study. Women of childbearing potential were included if they were using an approved contraception method and were not pregnant or breastfeeding. Subjects with a history or evidence of an acute or chronic illness, coagulopathy or thromboembolic disease were excluded, as were subjects with other protocol-defined medical histories or clinical findings considered to represent an unacceptable bleeding risk or coagulopathy. Subjects with any contraindications to PCC or apixaban administration, or any condition that might alter apixaban pharmacokinetics, including concomitant medication, were also excluded.
Study procedures
Blood samples for PD and pharmacokinetic (PK) analyses were collected prior to apixaban administration on day 1 and day 4, and then serially on day 4 at 0.5 h, 1 h, 2 h, 3 h, 3.5 h, 4 h, 5 h, 7 h, 9 h, 12 h, 24 h, 48 h and 72 h after apixaban administration. All samples were drawn through an indwelling catheter or via direct venipuncture. Blood samples were collected into 4.5-mL (TGA, PT/INR and APTT samples) or 1.8-mL (AXA and PK samples) sodium citrate tubes, gently inverted for complete mixing, and then centrifuged at room temperature. TGA samples were centrifuged for 15 min at 2000 9 g, after which the plasma was transferred to a brown cap tube and recentrifuged at 2500 9 g for 15 min, with the remaining plasma being transferred to a polypropylene cryotube for storage. PT/INR, APTT and AXA samples were centrifuged at 2000 9 g, and PK samples were centrifuged for 15 min at 1500 9 g; the plasma from each sample was transferred to its own polypropylene cryotube for storage. All plasma samples were stored frozen at À70°C until being shipped on dry ice for analysis. Safety assessments included physical examinations, vital sign measurements, 12-lead electrocardiograms (ECGs), and clinical laboratory testing performed at specified intervals during the study. Subjects were monitored for adverse events (AEs) throughout the study and for 30 days following completion of dosing.
Assay methods
TGA parameters were determined with the Calibrated Automated Thrombogram system (Diagnostica Stago, Parsippany, NJ, USA) by Esoterix Coagulation Laboratory (Englewood, CO, USA). Briefly, thrombin formation was triggered with 5 pM recombinant tissue factor and 4 lM phospholipids (PPP Reagent; Diagnostica Stago) [18] . The thrombin concentration in each sample was calculated over a period of 90 min by measuring cleavage of a fluorogenic substrate in the context of a paired (non-clotting) calibration sample. A dedicated software program (THROMBINOSCOPE; Thrombinoscope BV, Maastricht, the Netherlands) was used to calculate TGA parameters [18, 19] .
PT [20] .
Apixaban plasma concentration was determined during the period of known analyte stability by use of a validated liquid chromatography-tandem mass spectrometry method with a lower limit of quantification of 1 ng mL À1 [21] . Individual subject PK parameters were derived from the plasma concentration-time data by non-compartmental methods with a validated PK analysis program (KINET-ICA 5.0 within ETOOLBOX [version 2.7] ).
Endpoints
The primary endpoints were the ETP change from pre-PCC baseline and the ETP change from day 1 baseline. Pre-PCC baseline for each period was defined as the sample collected on day 4, 3 h after apixaban administration prior to the start of infusion. Day 1 baseline was defined as the sample collected on day 1, prior to each period's first apixaban dose (0 h).
Secondary endpoints included change from pre-PCC baseline and change from day 1 baseline for other TGA parameters (lag time, peak, time to peak, and velocity index), APTT, PT, INR, and AXA. Multiple-dose PK parameters included maximum observed plasma concentration (C max ), time to C max (T max ), trough observed plasma concentration at the end of one dosing interval (12 h; C min ), area under the concentration-time curve from time of administration to 12 h postdose (AUC 0-12 h ), area under the concentration-time curve from time of administration to 24 h postdose (AUC 0-24 h ), and terminal elimination half-life determined following the last dose of apixaban on day 4 of each period.
Sample size and statistical analysis
Twelve subjects per treatment provided at least 99% power to detect a difference of 420 nM min in mean ETP change from pre-PCC baseline (an approximately 60% Fig. 1 . Study design. In each period, apixaban 10 mg twice daily was administered on days 1-3 and as a single 10-mg dose on the morning of day 4. On day 4 of each period, 3 h after apixaban administration, subjects were given a 30-min infusion of either saline (placebo), Cofact 50 IU kg À1 , or Beriplex 50 IU kg reduction in the effect of apixaban, assuming that the maximum effect on ETP is 700 nM min). With 12 subjects per treatment, there was 96% power to conclude that there was an absence of difference (within AE 280 nM min [15%] of day 1 baseline) between day 1 baseline and the day 4 30-min post-PCC measurement, at a two-sided significance level of 0.05. Data for a given treatment were included in the statistical analysis from subjects who received the full study medication dose. For the primary analysis, the ETP change from pre-PCC baseline was evaluated by use of a mixed-effect model with treatment, sequence and period as main effects, pre-PCC baseline value as covariate, and measurements within subjects as repeated measures. An unstructured covariance matrix was used to represent the correlation of the repeated measures within each subject. The model provided least-squares mean estimates, standard errors, and two-sided 95% confidence intervals (CIs) for ETP change from pre-PCC baseline between each of the two PCC treatments and placebo. The two-sided Pvalue was calculated for each PCC treatment.
The ETP change from day 1 baseline was evaluated by use of a similar mixed-effect model with treatment (PCC treatments only), sequence, and period as main effects, the reduction in ETP caused by apixaban at pre-PCC baseline as a covariate, and measurements within subjects as repeated measures. An unstructured covariance matrix was used to represent the correlation of the repeated measures within each subject. The model provided least-squares mean estimates, standard errors and two-sided 95% CIs for ETP change from day 1 baseline within each PCC treatment. No effect was defined as within AE 280 nM min or 15% of day 1 baseline for the post-PCC versus pre-apixaban comparison for ETP.
Secondary PD endpoints were analyzed in a similar manner to ETP for both PCC treatments (the post-PCC versus day 1 baseline comparison is not applicable for AXA, as AXA is unmeasurable in the absence of apixaban). Endpoints were analyzed sequentially, beginning with the primary endpoints as described above. The secondary endpoints were then analyzed in the following order until either all comparisons of interest were made, or the two-sided P-value for a comparison of interest was > 0.05: other TGA parameters (lag time, time to peak, peak, and velocity index), PT, INR, APTT, and AXA. No multiplicity adjustments were made.
To assess apixaban pharmacokinetics following PCC administration, logAUC 0-12 h and logAUC 0-24 h of apixaban measured on day 4 were analyzed by use of a linear mixed-effect model, including treatment, period, and sequence as fixed effects, and measurements within subjects as repeated measures. Point estimates and 90% CIs for ratios of geometric means were generated for comparison of AUC 0-12 h and AUC 0-24 h between each of the two PCC treatment groups and the placebo group. All analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
A total of 15 healthy subjects were randomized and completed the study from 28 ), owing to interruption of the infusion. This subject subsequently received placebo and Beriplex as planned; the PD and PK data from these treatment periods were included in the related statistical analyses.
Subjects were predominantly male (87%) and white (93%), with a mean age of 33 years (range: 22-45 years), and a mean body weight of 77 kg (range: 67-87 kg).
Prior to apixaban administration on day 1, ETP and other day 1 baseline PD measures were consistent across treatment groups (Table 2 ; Fig. 2A ). The day 1 baseline mean ETPs were 1624 nM min (standard deviation [SD] 223 nM min), 1652 nM min (SD 189 nM min) and 1611 nM min (SD 224 nM min) in the placebo, Cofact and Beriplex groups, respectively. The steady-state PD effects of apixaban (represented by the mean pre-PCC baseline) were also consistent across groups. Changes in ETP and other PD measures generally followed the apixaban plasma concentration-time profile; the greatest changes occurred around apixaban T max . Overall mean decreases in ETP from day 1 baseline to 3 h after apixaban dosing on day 4 (pre-PCC baseline) were: À 807 nM min (SD 298 nM min), À 841 nM min (SD 232 nM min) and À 793 nM min (SD 197 nM min) in the placebo, Cofact and Beriplex groups, respectively, representing an approximately 50% decrease across treatments.
Both PCCs, but not placebo, rapidly reversed the apixaban-mediated decreases in mean ETP ( Fig. 2A,B) . The mean increase from pre-PCC baseline for Cofact at the end of the 30-min infusion was statistically significant versus placebo (difference in adjusted mean change of 425.3 nM min [95% CI 219.8-630.7 nM min], P < 0.001). Although mean ETP (1326 nM min [SD 427 nM min]) remained below day 1 baseline at the end of the Cofact infusion, mean ETP was comparable to the steady-state apixaban predose (trough) value of 1302 nM min (SD 270 nM min). The effect of Beriplex at the end of infusion was less than that observed for Cofact, but appeared to be greater than the change following placebo administration. However, the effect of Beriplex was not statistically significant from that of placebo (difference in adjusted mean change of 90.6 nM min [95% CI À 31.3 to 212.4 nM min], P = 0.131; Table 2 ). Within 30 min of completion of Beriplex infusion, mean ETP was comparable to that achieved by Cofact (Fig. 2A) . Reversal of ETP to the day 1 baseline value occurred 4 h after initiation of each 30-min PCC infusion. Mean ETP continued 
Day 1 baseline was defined as the day 1 sample collected prior to the first apixaban dose (0 h) of each period. Pre-PCC baseline was defined as the predose sample collected on day 4, 3 h after the apixaban dose and before the start of the PCC or placebo infusion in each period. APTT, activated partial thromboplastin time; AXA, anti-activated factor X activity; CFB, change from baseline; CI, confidence interval; ETP, endogenous thrombin potential; Neo. CI+, Neoplastin CI+; PT, prothrombin time; Rec. 2G, RecombiPlasTin 2G; SD, standard deviation.
*Statistical
analyses were based on the change from pre-PCC baseline dose of each period. †The analysis excludes one subject who received a partial Cofact dose. to increase above the mean day 1 baseline value, with a maximum mean ETP being observed at 21 h after initiation of Cofact (51% mean ETP increase from day 1 baseline of 840 nM min) and Beriplex (34% mean ETP increase from day 1 baseline of 549 nM min). Thereafter, mean ETP decreased for both PCC treatments, but remained approximately 27% and 21% higher than day 1 baseline at the last observations for Cofact and Beriplex, respectively. Following placebo administration, mean ETP remained below the steady-state apixaban predose value for ≈ 9 h after infusion and returned to day 1 baseline ≈ 48 h after apixaban administration (45 h after initiation of infusion). PCC infusion yielded a more rapid increase in TGA peak height than did placebo. As seen for ETP, a statistically significant increase in peak height occurred upon completion of Cofact infusion. Peak height was comparable to the steady-state apixaban predose values approximately 3.5-5.5 h after both PCC infusions, and comparable to day 1 baseline approximately 24-45 h after PCC administration (Fig. 2C) . PCC administration showed little effect on TGA lag time, time to peak, or velocity index.
Regardless of the thromboplastin (RecombiPlasTin 2G or Neoplastin CI Plus) used, PT increased following administration of apixaban; rapid reversal was observed following infusion of either PCC (Cofact or Beriplex) as compared with placebo (Fig. 3A) . INR (data not shown) showed a trend similar to that of PT. Increased APTT was also evident following apixaban administration. Reversal of APTT was not observed following either PCC infusion; instead, there was a further increase in APTT (Fig. 3B) relative to placebo. In the Cofact group, mean APTT was 37.2 s at 3 h after apixaban administration, prior to infusion, and increased to 46.8 s by the end of infusion. Thereafter, APTT decreased and was lower than the pre-PCC value ≈ 8.5 h after infusion and comparable to placebo 48 h after apixaban administration (33.6 s versus 32.0 s for placebo). For Beriplex, the increase in mean APTT was less pronounced, increasing from 38.3 s prior to infusion to 41.5 s by the end of infusion. Thereafter, mean APTT decreased to a level comparable to placebo by 4 h after apixaban administration. PCC administration did not impact on apixaban-mediated changes in AXA (Fig. 3C) .
Apixaban PK parameters were comparable across all three groups (Table 3) . Neither PCC affected apixaban exposure; point estimates for ratios of adjusted geometric mean AUC 0-12 h and AUC 0-24 h were near unity, and the corresponding 90% CIs were entirely contained within an 80-125% no-effect interval. As shown in Fig. 4 , the apixaban concentration was at steady state on day 4, on the basis of similarity between the mean plasma concentrations observed on day 4 prior to and 12 h after apixaban administration (representative of one dosing interval).
There were no serious AEs, AEs leading to discontinuation, clinically relevant bleeding-related AEs or signs of thrombosis during the study, or during the 30-day followup after completion of study drug administration. A total of 10 treatment-emergent AEs were reported: four following administration of apixaban or apixaban and placebo, five following apixaban and Cofact administration, and one following apixaban and Beriplex administration. All had resolved by study completion. The most common AEs were nasopharyngitis (two subjects following apixaban and Cofact administration) and abdominal pain (one subject following apixaban administration, and one subject following apixaban and Beriplex administration). All other AEs were single events reported by individual subjects. All AEs were considered to be of mild intensity, except for one moderate headache (apixaban and Cofact). All but one AE (mild dizziness after Cofact administration) were considered to be unrelated to study drugs, including a mild right leg hematoma that occurred following administration of apixaban and saline. There were no clinically relevant changes in clinical laboratory, vital sign, or ECG assessments.
Discussion
Despite the advantages of DOAC therapy, the lack of a reversal agent is sometimes perceived as limiting their broader use [22] . In this study, apixaban steady-state PD effects were demonstrated by changes in several thrombin generation parameters, clotting time assessments, and AXA. A single 50 IU kg À1 four-factor PCC infusion had a significant effect on apixaban steady-state pharmacodynamics and resulted in a more rapid return to day 1 baseline for several PD measures relative to placebo. Apixaban administration, with and without PCC treatment, was generally well tolerated. Our results contribute to the growing body of in vitro, animal, and human data [14] [15] [16] [17] [23] [24] [25] [26] [27] demonstrating that PCCs, in this case fourfactor PCCs, reverse the PD effects of apixaban. Fig. 2 . Effect of administration of apixaban with placebo, Cofact or Beriplex on measures of coagulation factors. (A) endogenous thrombin potential (ETP) over a period of 72 h, (B) ETP over a period of 10 h, and (C) thrombin generation assay (TGA) peak height over a period of 72 h. Error bars denote standard deviation. Dotted horizontal lines represent day 1 baseline calculated as the mean of day 1 baseline observations from all three periods. The infusion of prothrombin complex concentrate (or placebo) was started 3 h after apixaban administration (hour 3) and completed 30 min later (hour 3.5). Data were excluded for one subject who received a partial dose of Cofact (Apixaban + Cofact). Apixaban + placebo = apixaban 10 mg twice daily on days 1-3, and apixaban 10-mg single dose + placebo on day 4; Apixaban + Cofact = apixaban 10 mg twice daily on days 1-3, and apixaban 10-mg single dose + Cofact 50 IU kg À1 on day 4; Apixaban + Beriplex = apixaban 10 mg twice daily on days 1-3, and apixaban 10-mg single dose + Beriplex 50 IU kg À1 on day 4. PCC reversal of the PD effects of direct FXa inhibitors in the TGA has been observed in multiple preclinical (animal and in vitro bleeding models) [14, 15, 23, 24] and clinical (phase 1, healthy, non-bleeding subjects) [16, 17, [25] [26] [27] studies, which have shown increased ETP following PCC administration. Administration of Point estimates and 90% CIs for ratios of geometric means were generated for comparison of AUC 0-12 h between each of the two PCC treatment groups and the placebo group (Cofact versus placebo, and Beriplex versus placebo). AUC 0-12 h , area under the plasma concentrationtime curve over one dosing interval; C max , maximum observed plasma concentration; C min , trough observed plasma concentration at the end of one dosing interval; CI, confidence interval; CV, coefficient of variation; Gmean, geometric mean; GMR, geometric mean ratio; PCC, prothrombin complex concentrate; SD, standard deviation; t 1/2 , terminal elimination half-life; T max , time to maximum observed plasma concentration. *The analysis excludes one subject who received a partial Cofact dose. . Apixaban concentration-time profiles with and without prothrombin complex concentrate administration. Error bars denote standard deviation. Data were excluded for one subject who received a partial dose of Cofact (Apixaban + Cofact). Apixaban + placebo = apixaban 10 mg twice daily on days 1-3, and apixaban 10-mg single dose + placebo on day 4; Apixaban + Cofact = apixaban 10 mg twice daily on days 1-3, and apixaban 10-mg single dose + Cofact 50 IU kg À1 on day 4; Apixaban + Beriplex = apixaban 10 mg twice daily on days 1-3, and apixaban 10-mg single dose + Beriplex 50 IU kg À1 on day 4. Fig. 3 . Effect of prothrombin complex concentrate (PCC) on the anticoagulant effect of apixaban. Assessed by: (A) prothrombin time (PT) (RecombiPlasTin 2G), (B) activated partial thromboplastin time (APTT), and (C) anti-activated factor X activity (AXA). Error bars denote standard deviation. Dotted horizontal lines represent day 1 baseline calculated as the mean of day 1 baseline observations from all three periods. The infusion of PCC (or placebo) was started 3 h after apixaban administration (hour 3) and completed 30 min later (hour 3.5). Data were excluded for one subject who received a partial dose of Cofact (Apixaban + Cofact). Apixaban + placebo = apixaban 10 mg twice daily on days 1-3, and apixaban 10-mg single dose + placebo on day 4; Apixaban + Cofact = apixaban 10 mg twice daily on days 1-3, and apixaban 10-mg single dose + Cofact 50 IU kg À1 on day 4; Apixaban + Beriplex = apixaban 10 mg twice daily on days 1-3, and apixaban 10-mg single dose + Beriplex 50 IU kg À1 on day 4. LMWH, low molecular weight heparin. À1 Kcentra (Beriplex) reversed the effect of apixaban on peak thrombin generation in healthy, non-bleeding subjects given apixaban 5 mg twice daily for 2.5 days [17] . Single 50 IU kg À1 infusions of Cofact, Beriplex or Profilnine SD (a three-factor PCC) reversed the effects of rivaroxaban on ETP in healthy, non-bleeding subjects [25, 26] . Dose-related ETP increases have been observed following infusion of 37.5 IU kg À1 and 25 IU kg
À1
Cofact into healthy, non-bleeding subjects given apixaban 10 mg twice daily [16] , as well as following infusions of 10, 25 or 50 IU kg À1 Beriplex into healthy, non-bleeding subjects given a single dose of edoxaban 60 mg [27] . The overall effect of PCC on ETP in these studies appears to be consistent with our findings, which demonstrated that ETP increased rapidly immediately after infusion, and then showed a continued, more gradual, increase. The absolute effect on ETP and effects on other TGA parameters (peak height and lag time) are somewhat less consistent across studies. This is not unexpected, as TGA methods can vary, and differences in tissue factor or tissue factor concentration can impact on results [14, 28, 29] . Thrombosis and disseminated intravascular coagulopathy are known risks following PCC administration, particularly with repeated dosing [30, 31] . The overall safety profile of apixaban was consistent with that observed in previous repeat-dose studies in healthy subjects [32] [33] [34] . There were no signs or symptoms of thrombosis in this study or other clinical studies in healthy subjects given a direct FXa inhibitor and a three-factor or four-factor PCC [16, [25] [26] [27] ; however, ETP has exceeded baseline values following PCC administration in each study, even after a PCC dose as low as 10 IU kg À1 . Unlike previous studies, which did not show a return to baseline, our results indicate that the increase in ETP peaked ≈ 21 h after initiation of PCC administration and slowly declined, trending towards day 1 baseline in the following 48 h. Even though thrombotic events were not observed in these healthy subject studies, it is not known whether similar increases in ETP would pose a concern in patients experiencing bleeding, or in those with additional risk factors for thrombotic events. Therefore, the optimal dose and dosing regimen of PCCs used to manage DOACrelated bleeding have not been established, and warrant further study to better understand the balance between managing bleeding without the development of a potentially detrimental prothrombotic state. Thromboplastin-related differences in DOAC response have been well documented for the PT assay [20, 35] . This was also evident in this study, in which a thromboplastindependent response persisted after four-factor PCC administration. Following PCC infusion, the mean decreases in PT, as determined with RecombiPlasTin 2G, were 2.1 s and 1.6 s for Cofact and Beriplex, respectively, versus a mean increase of 0.34 s for placebo. Similar results were obtained with Neoplastin CI Plus, although the PT increase following apixaban administration and the decrease following PCC infusion were less pronounced than those observed with RecombiPlasTin 2G.
In contrast to ETP, peak height, PT, and INR reversal, further prolongation of APTT occurred after PCC infusion. Increases in APTT following PCC administration have been reported previously [26, 35] . This paradoxical effect does not appear to be related to consumption of coagulation factors [36] . It has been suggested that this effect may be attributable to the presence of heparin in certain PCC products [26, 37] , although this does not appear to be likely, according to the results of our study. Cofact, which does not contain heparin, appeared to result in a more substantial increase in APTT than Beriplex, which may contain up to approximately 3200 IU of heparin per 50 IU kg À1 infusion. It may be that the APTT increase is an artefact resulting from interactions between PCC components (prothrombin) and the APTT assay [38] ; however, there is not yet a clear understanding of the underlying mechanism.
Neither apixaban pharmacokinetics nor AXA were affected by PCC administration. We previously demonstrated a direct, linear correlation between AXA, determined with a one-step chromogenic method, and apixaban plasma concentration [20, 39] . The addition of excess exogenous FXa to the AXA sample required by this method may mask changes in endogenous FX or FXa concentration, even after a 50 IU kg À1 four-factor PCC infusion. Therefore, one-step AXA assays, such as the one used in this study, may give a better reflection of drug concentration than the in vivo anticoagulant effect of the drug. This study demonstrated reversal of apixaban pharmacodynamics by two four-factor PCC products, Cofact and Beriplex, in healthy subjects; however, we do not know whether these PD changes in healthy subjects will translate to cessation of bleeding in a direct FXa inhibitortreated patient, or what PCC dose provides the optimal balance between cessation of bleeding and thrombotic risk. The magnitudes of the effects that Cofact and Beriplex had on apixaban pharmacodynamics in this study appeared to differ. These differences do not appear to be related to heparin content; further evaluation is beyond the scope of this study. It is possible that the effects of other PCCs will differ from what we have observed, especially when more substantial differences in the composition of the product exist, as with three-factor and activated-factor PCCs. When the effects of PCCs on apixaban pharmacodynamics are evaluated, it is important to consider the potential impact of laboratory test selection and methods, because it appears that results may be influenced by choice of reagents or interference by PCC administration, or be a reflection of drug concentration rather than pharmacodynamics.
Withholding apixaban administration for 24 h or 48 h, depending on bleeding risk, allowing the drug's elimination from the systemic circulation, may be an acceptable way to manage the risk of bleeding prior to elective surgery or invasive procedures [40] . Orally administered activated charcoal reduces the absorption of apixaban, thereby lowering the apixaban plasma concentration, and may be useful when more rapid removal of apixaban is desired [40, 41] . However, there are a growing number of case reports [42] [43] [44] and guidelines [45, 46] suggesting that PCCs may have a role in the more acute management of patients experiencing bleeding while being treated with a direct FXa inhibitor. Further research is needed to address unanswered questions left by this, and other healthy subject studies, to determine exactly what role PCCs may have, especially as work on specific FXa inhibitor reversal agents progresses.
Conclusions
Cofact and Beriplex rapidly reversed the steady-state PD effects of apixaban in several coagulation assessments. By the end of infusion, Cofact significantly reduced the effect of apixaban on ETP, while Beriplex appeared to reduce the effect of apixaban; however, the effect did not reach statistical significance. Four-factor PCC administration had no effect on apixaban pharmacokinetics or AXA. This study supports further research aimed at understanding the effects of four-factor PCCs in apixaban-treated patients.
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